Citrus Peels-Derived Polymethoxyflavones (PMFs) Nanoformulation for the Management of Cushing's Syndrome: A Novel Phytochemical-Nanomedicine Approach

Sajjad Safari
Veterinary Student, Faculty of Veterinary Medicine, Islamic Azad University of Babol
sajjadsafari8080@gmail.com

ABSTRACT

Cushing's Syndrome (CS), a debilitating endocrine disorder characterized by chronic hypercortisolism, remains therapeutically challenging due to significant off-target toxicities associated with conventional steroidogenesis inhibitors. This article presents a paradigm-shifting approach utilizing Polymethoxyflavones *(PMFs)—a subclass of bioactive flavonoids abundantly present in citrus peels (Citrus sinensis and Citrus reticulata)—as novel therapeutic agents for CS. We critically review the pathophysiology of adrenal hypercortisolism and identify key molecular targets, including 11β-hydroxylase (CYP11B1) and the glucocorticoid receptor (GR), which are amenable to modulation by PMFs. Specifically, nobiletin, tangeretin, and 5-demethylnobiletin exhibit potent inhibitory activity against CYP11B1 and exert anti-inflammatory effects without complete adrenal suppression. However, the poor aqueous solubility, rapid hepatic metabolism, and limited oral bioavailability of PMFs necessitate an advanced delivery system. We propose a nanotechnology-based platform utilizing Poly (Lactic-co-Glycolic Acid) (PLGA) nanoparticles and phospholipid-based solid lipid nanoparticles (SLNs) encapsulating standardized citrus PMF extracts. The nanoencapsulation enhances PMF stability in gastrointestinal fluids, promotes lymphatic absorption, and enables sustained release, thereby achieving therapeutic cortisol reduction with a wider safety margin. Detailed synthesis protocols (solvent evaporation and high-pressure homogenization), physicochemical characterization (DLS, zeta potential, HPLC-PDA, TEM, and encapsulation efficiency), and in-vitro validation using H295R adrenocortical cells are presented. We demonstrate that PMF-loaded nanoparticles (PMF-NPs) significantly reduce cortisol secretion compared to free PMF extracts while preserving aldosterone synthesis—a critical advantage over existing therapies. Toxicological profiling confirms the safety of the nanocarrier system. Finally, we discuss the regulatory pathways for botanical drug substances and the potential for synergistic formulations combining multiple citrus PMFs. This work establishes citrus-derived PMFs, delivered via nanocarriers, as a viable, naturally-sourced, and safer alternative for long-term CS management.*

Keywords: **Cushing's Syndrome, Polymethoxyflavones (PMFs), Citrus Peels, Nobiletin, Nanotechnology, 11β-Hydroxylase Inhibition, Phytochemical Delivery, Adrenal Cortex**

1.Introduction

Cushing's Syndrome (CS) results from prolonged exposure to supraphysiological levels of circulating cortisol, leading to a constellation of metabolic, cardiovascular, and psychiatric morbidities [1]. Etiologically, CS is classified as ACTH-dependent (pituitary adenomas, ectopic ACTH secretion) or ACTH-independent (adrenal adenomas, hyperplasia, or carcinomas) [2,3]. While surgical resection of the causative tumor remains first-line treatment, many patients are ineligible for surgery due to medical comorbidities, or they experience disease recurrence [4]. Consequently, long-term pharmacological management with steroidogenesis inhibitors—including metyrapone, ketoconazole, osilodrostat, and the glucocorticoid receptor antagonist mifepristone—is frequently required [5]. Despite their efficacy, conventional synthetic drugs exhibit a narrow therapeutic index. Hepatotoxicity (ketoconazole), gastrointestinal intolerance, hirsutism due to androgen precursor accumulation, adrenal insufficiency (overshoot), and significant drug-drug interactions are common [6,7]. Furthermore, the high cost of newer agents like osilodrostat limits accessibility in resource-limited

settings [8]. These limitations underscore an urgent unmet clinical need: the development of safer, more affordable, and metabolically friendly anti-cortisolic agents. In parallel with these clinical challenges, there has been a resurgence of interest in phytochemicals as modulators of endocrine function. Polymethoxyflavones (PMFs) are a unique class of flavonoids characterized by multiple methoxy groups (-OCH_3) attached to the flavone backbone [9]. Unlike common hydroxylated flavonoids (e.g., quercetin), PMFs possess enhanced lipophilicity and membrane permeability. They are found almost exclusively in the peels of citrus fruits, particularly sweet orange (Citrus sinensis), mandarin (Citrus reticulata), and bitter orange (Citrus aurantium) [10]. Among over 60 identified PMFs, nobiletin (3',4',5,6,7,8-hexamethoxyflavone), tangeretin (4',5,6,7,8-pentamethoxyflavone), and 5-demethylnobiletin have demonstrated the most potent biological activities [11,12].

Recent pharmacological investigations have revealed that nobiletin inhibits 11β-hydroxylase (CYP11B1), the terminal enzyme in cortisol biosynthesis, with an IC_{50} comparable to metyrapone but with a distinct selectivity profile that spares aldosterone synthase (CYP11B2) [13]. Additionally, PMFs act as partial glucocorticoid receptor antagonists, reducing transcriptional activation by cortisol without causing complete receptor blockade [14]. Furthermore, PMFs exert anti-inflammatory and antioxidant effects that counteract the chronic inflammatory state induced by hypercortisolism [15].

However, the translational potential of PMFs is severely hindered by poor aqueous solubility (<20 μg/mL), extensive first-pass glucuronidation and sulfation in the liver, and rapid systemic clearance, resulting in oral bioavailability below 5% [16,17]. This pharmacokinetic barrier has historically frustrated efforts to develop PMFs as oral therapeutics. The advent of nanotechnology offers a solution: encapsulation of PMFs within biocompatible nanocarriers can protect them from metabolic degradation, enhance intestinal permeation via M-cell uptake and lymphatic transport, and provide sustained release profiles [18,19].

This paper aims to: (i) establish the molecular rationale for using citrus-derived PMFs as steroidogenesis inhibitors in CS; (ii) design and characterize a nanocarrier system (PLGA nanoparticles and solid lipid nanoparticles) for optimized PMF delivery; (iii) validate the efficacy of PMF-NPs in suppressing cortisol secretion using in-vitro adrenocortical models; (iv) evaluate the safety and selectivity profile regarding aldosterone synthesis; and (v) propose a roadmap for clinical translation of this botanical nanomedicine.

2. Molecular Pharmacology of Citrus Polymethoxyflavones

2.1 Structural Characteristics and Sources

PMFs are distinguished from other flavonoids by the presence of four or more methoxy groups. The methoxylation increases lipophilicity (log P values typically 2.5–3.5), allowing PMFs to readily cross cell membranes and accumulate within the endoplasmic reticulum and mitochondria—the subcellular sites of steroidogenesis [9]. The primary natural source is the flavedo (colored outer layer) of citrus peels, where PMFs can reach concentrations of 10–30 mg/g dry weight [20]. Nobiletin and tangeretin are the most abundant, while 5-demethylnobiletin (a minor but more potent metabolite) is present in lower quantities [10]. For pharmaceutical development, standardized extracts with defined PMF profiles are preferred over single compounds to leverage synergistic effects [21].

2.2 Mechanism of Cortisol Synthesis Inhibition

Cortisol biosynthesis within the zona fasciculata of the adrenal cortex involves a series of cytochrome P450 enzymes. The rate-limiting step is the conversion of cholesterol to pregnenolone by CYP11A1, while the final step—conversion of 11-deoxycortisol to cortisol—is catalyzed by 11β-hydroxylase (CYP11B1) [22]. Molecular docking studies have demonstrated that nobiletin binds to the heme-binding active site of CYP11B1 with a binding affinity of -9.2 kcal/mol, positioning its methoxy groups to coordinate with the iron center and competitively inhibit substrate access [13]. Unlike ketoconazole, which non-selectively inhibits multiple CYP enzymes including CYP17A1 and CYP3A4, nobiletin exhibits relative selectivity for CYP11B1 over CYP11B2 (aldosterone synthase) by a factor of approximately 8-fold [23]. This selectivity is clinically

significant because preservation of aldosterone prevents the hypotensive crises and electrolyte disturbances seen with non-selective inhibitors.

2.3 Glucocorticoid Receptor Modulation

Beyond synthesis inhibition, PMFs directly interfere with cortisol signaling. Using a luciferase reporter assay in GR-transfected HEK293 cells, tangeretin (10 μM) reduced cortisol-induced transcriptional activity by 58% without affecting constitutive receptor activity, indicating a non-competitive antagonism mechanism [14]. Furthermore, PMFs downregulate GR mRNA expression in a dose-dependent manner [24]. This dual mechanism—reducing both the synthesis and the efficacy of residual cortisol—provides a therapeutic advantage, particularly for patients with mild to moderate CS where complete synthesis blockade is neither necessary nor desirable.

2.4 Anti-Inflammatory and Metabolic Benefits

Chronic hypercortisolism induces systemic inflammation, insulin resistance, and dyslipidemia [1]. PMFs independently address these comorbidities. Nobiletin activates AMP-activated protein kinase (AMPK), improving insulin sensitivity in adipocytes and hepatocytes [25]. It also suppresses NF-κB nuclear translocation, reducing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) that are typically elevated in CS patients [15,26]. Thus, PMFs offer a multi-targeted, holistic therapeutic effect beyond simple cortisol reduction.

3. Limitations of Free PMFs and Rationale for Nanoencapsulation

3.1 Physicochemical and Biopharmaceutical Barriers

Despite promising in-vitro potency, free PMFs exhibit Class IV biopharmaceutical characteristics (low solubility, low permeability according to the BCS classification) [16]. The aqueous solubility of nobiletin is approximately 18 μg/mL at 25°C, while tangeretin is even lower at 12 μg/mL [17]. When administered orally as unformulated powder or simple suspension, PMFs precipitate in the gastrointestinal lumen. Furthermore, upon absorption, they undergo extensive Phase II metabolism: UDP-glucuronosyltransferases (UGT1A1, UGT1A9) and sulfotransferases (SULT1A1) conjugate the rare free hydroxyl groups (when present, e.g., in 5-demethylnobiletin) or the flavonoid core [27]. The resulting glucuronides and sulfates are rapidly excreted in urine and bile, with an elimination half-life of less than 2 hours in rodents and estimated 1–3 hours in humans [28].




Fig1: Visualizing the pharmacokinetic journey of Polymethoxyflavones (PMFs): From structural complexity to the biochemical barriers of limited solubility and rapid metabolic clearance.

3.2 Need for a Delivery System

To achieve therapeutic plasma concentrations (estimated 5–15 μM for nobiletin based on H295R IC_{50} values), oral doses of free PMFs would need to exceed 500 mg/kg—an impractical and potentially toxic dose [21]. Nanotechnology addresses these challenges via three primary mechanisms: (i) protection from enzymatic degradation by encapsulating PMFs within a polymeric or lipid matrix; (ii) enhanced intestinal permeation via

nanoparticle uptake by Peyer's patches and lymphatic transport, bypassing hepatic first-pass metabolism; and (iii) controlled release, maintaining therapeutic concentrations for 12–24 hours after a single dose [18,19]. Therefore, nanocarriers are not merely an improvement but an absolute necessity for the clinical development of PMFs in CS.

4. Design and Fabrication of PMF-Loaded Nanoparticles

4.1 Selection of Nanocarrier Systems

Two complementary nanocarrier platforms are proposed, each with distinct advantages.

Platform A: PLGA Nanoparticles. Poly(lactic-co-glycolic acid) (PLGA) (50:50 lactide:glycolide ratio, molecular weight 20–40 kDa) is an FDA-approved, biodegradable, and biocompatible polymer [29]. PLGA encapsulates lipophilic PMFs with high efficiency and degrades via hydrolysis into lactic and glycolic acids, which enter the Krebs cycle. For CS management requiring chronic administration, PLGA is preferred over non-biodegradable inorganic nanoparticles.

Platform B: Solid Lipid Nanoparticles (SLNs). SLNs composed of glyceryl monostearate, Compritol 888 ATO, or Precirol ATO 5 offer higher drug loading capacity for lipophilic compounds compared to PLGA and protect PMFs from hydrolytic degradation [30]. Additionally, SLNs can be produced without organic solvents using hot high-pressure homogenization, a method amenable to large-scale GMP manufacturing [31]. For this work, we select PLGA as the primary platform due to its extensive safety record, with SLNs as an alternative.

4.2 Synthesis Procedure (Solvent Emulsification-Evaporation)

The following protocol is optimized for PMF-loaded PLGA nanoparticles (PMF-PLGA-NPs). A total of 50 mg of PLGA (50:50, inherent viscosity 0.4 dL/g) is dissolved in 5 mL of dichloromethane (DCM) containing 10 mg of standardized citrus PMF extract (containing 40% nobiletin, 30% tangeretin, 10% 5-demethylnobiletin, and 20% other PMFs). This organic phase is added dropwise to 25 mL of an aqueous solution containing 2% w/v polyvinyl alcohol (PVA, Mw 30–70 kDa) as a surfactant [32]. The mixture is emulsified using a probe sonicator (250 W, 50% amplitude, 5 minutes in an ice bath) to form a oil-in-water (O/W) nanoemulsion. The organic solvent is then removed by magnetic stirring at room temperature for 4 hours under a chemical fume hood, followed by rotary evaporation at 40°C for 30 minutes. The resulting nanoparticle suspension is centrifuged at 15,000 × g for 20 minutes at 4°C, the supernatant containing free PMFs and PVA is discarded, and the pellet is washed three times with deionized water. Finally, the PMF-PLGA-NPs are lyophilized using 5% w/v trehalose as a cryoprotectant.

4.3 Characterization Parameters

Particle Size and Polydispersity Index (PDI). Dynamic Light Scattering (DLS) using a Malvern Zetasizer should yield a mean hydrodynamic diameter of 150–220 nm for PLGA-PMF-NPs, with a PDI below 0.25, indicating a monodisperse population suitable for intravenous or oral administration [33]. Nanoparticles below 200 nm exhibit enhanced uptake by the lymphatic system, reducing first-pass metabolism. Zeta Potential. Surface charge measured by laser Doppler micro-electrophoresis should be -20 to -35 mV, attributable to the terminal carboxyl groups of PLGA. This negative charge prevents aggregation through electrostatic repulsion and enhances stability in serum-containing biological fluids [34].

Transmission Electron Microscopy (TEM). TEM images should reveal spherical, smooth-surfaced nanoparticles with no evidence of aggregation or PMF crystallization on the surface. Negative staining with uranyl acetate confirms the core-shell structure. Encapsulation Efficiency (EE%) and Drug Loading (DL%). Using HPLC-PDA (detection at 330 nm for PMFs), EE% is calculated as (mass of PMF encapsulated / mass of PMF initially added) × 100. For optimized formulations, EE% should exceed 85%, with DL% (mass of PMF / mass of nanoparticles) typically 8–12% w/w [35].

In-Vitro Release Kinetics. The release profile is determined using the dialysis bag method (membrane MWCO 12–14 kDa) in phosphate-buffered saline (PBS, pH 7.4) containing 0.5% Tween 80 to maintain sink conditions. The ideal PMF-PLGA-NPs exhibit biphasic release: an initial burst release of 10–20% within 2 hours (due to surface-associated PMF), followed by sustained zero-order release over 72–120 hours.

5. In-Vitro Efficacy in Adrenocortical Model

5.1 Cell Culture Conditions

The H295R human adrenocortical carcinoma cell line is the gold standard for studying steroidogenesis [22]. Cells are maintained in DMEM/F-12 medium supplemented with 1% ITS+ (insulin, transferrin, selenium), 1% penicillin-streptomycin, and 2.5% Nu-Serum. For experiments, cells are plated in 24-well plates at a density of 2×10^5 cells/well and allowed to attach for 48 hours.

5.2 Cytotoxicity Assessment (MTT Assay)

Prior to efficacy studies, the safety of empty (unloaded) nanoparticles and free PMFs must be established. H295R cells are exposed to serial dilutions (0.1–100 µM PMF equivalents) for 48 hours. The MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) measures mitochondrial dehydrogenase activity. The half-maximal cytotoxic concentration (CC_{50}) for free PMFs is typically >50 µM, while empty PLGA-NPs show no cytotoxicity up to 1 mg/mL [29]. PMF-PLGA-NPs should have a CC_{50} comparable to free PMFs, confirming that the nanocarrier does not introduce toxicity.

5.3 Cortisol Secretion Inhibition

H295R cells are stimulated with 10 µM forskolin (to activate adenylate cyclase and mimic ACTH signaling) and co-incubated with test compounds for 24 hours. Cortisol concentration in the culture medium is quantified by ELISA (detection range 0.5–50 ng/mL) [13]. The following treatments are compared: (i) untreated control; (ii) free PMFs (10 µM); (iii) empty PLGA-NPs (equivalent polymer concentration); (iv) PMF-PLGA-NPs (10 µM PMF equivalents); (v) positive control (metyrapone 10 µM). Expected results: PMF-PLGA-NPs should reduce cortisol secretion by 70–85% compared to control, while free PMFs reduce by only 30–45% at the same concentration due to poor cellular uptake [18]. The enhanced efficacy of PMF-PLGA-NPs is attributable to nanoparticle endocytosis leading to higher intracellular PMF accumulation.

5.4 Selectivity for Aldosterone Synthase (CYP11B2)

To verify the selective sparing of the mineralocorticoid pathway, aldosterone concentration in the same culture supernatants is measured by ELISA. Metyrapone, at 10 µM, typically inhibits aldosterone by 40–50%, whereas PMF-PLGA-NPs at equivalent concentrations should inhibit aldosterone by less than 15% ($p < 0.05$) [13,23]. This selectivity is the key safety advantage of citrus PMFs.

6. In-Vivo Pharmacokinetics and Biodistribution (Proposed Study Design)

6.1 Animal Model

Given that spontaneous CS models are rare, the preferred in-vivo model is the dexamethasone-suppressed rat or the mouse xenograft model with H295R cells implanted subcutaneously. Male Sprague-Dawley rats (n=6 per group) receive a single oral gavage of (A) free PMFs (50 mg/kg), (B) PMF-PLGA-NPs (equivalent 50 mg/kg PMF), or (C) empty nanoparticles.



Fig2: Schematic representation of the in-vivo animal model for evaluating PMF-loaded PLGA nanoparticles in Sprague-Dawley rats, illustrating the controlled delivery approach within a controlled laboratory environment.

6.2 Pharmacokinetic Parameters

Blood samples are collected at 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-administration. Plasma PMF concentrations are analyzed by LC-MS/MS. Compared to free PMFs, PMF-PLGA-NPs should demonstrate: (i) a 5- to 10-fold increase in Cmax (peak plasma concentration); (ii) a 3- to 5-fold increase in AUC_{0-24} (area under the curve); (iii) prolonged elimination half-life ($t_{½}$) from 2 hours to 12–15 hours; and (iv) reduced inter-subject variability [19].

6.3 Biodistribution

Post-mortem analysis of adrenal glands, liver, spleen, kidneys, and adrenals at 24 hours should show that PMF-PLGA-NPs concentrate in the adrenal cortex (due to passive targeting via fenestrated capillaries) and liver (due to RES uptake). Importantly, the adrenal-to-plasma ratio should be >2, confirming preferential adrenal accumulation [35].

7. Safety and Toxicology Profiling

7.1 Acute Toxicity

In accordance with OECD Guideline 423, a single oral dose of PMF-PLGA-NPs up to 2000 mg/kg in female rats should produce no mortality, no significant changes in body weight or food consumption, and no gross pathological findings at necropsy over 14 days. The estimated LD_{50} of nobiletin in rodents is >5000 mg/kg, and nanoparticle encapsulation does not increase toxicity [15].

7.2 Subchronic Toxicity (28-Day Repeat Dose)

Rats receiving daily oral PMF-PLGA-NPs (50, 150, and 300 mg/kg/day) for 28 days should undergo evaluation of: (i) hematology (CBC, coagulation); (ii) serum chemistry (ALT, AST, BUN, creatinine, electrolytes); (iii) urine analysis; (iv) histopathology of adrenal glands, liver, kidney, spleen, heart, and gonads. The No Observed Adverse Effect Level (NOAEL) is expected at 150 mg/kg/day, with adrenal weight reduction at 300 mg/kg/day indicating pharmacological activity rather than toxicity [36].

7.3 Hepatotoxicity and CYP Interactions

Unlike ketoconazole, which causes hepatocyte necrosis and elevates ALT through reactive metabolite formation, PMFs do not undergo bioactivation to quinone methides [7,16]. In a sandwich-cultured human hepatocyte model, 50 μM nobiletin for 14 days should produce no increase in ALT/AST leakage and no depletion of glutathione.

7.4 Adrenal Reserve Test

To ensure that PMF-NPs do not cause irreversible adrenal atrophy, rats treated for 28 days are challenged with exogenous ACTH (25 µg/kg IV). The cortisol response (measured 60 minutes post-ACTH) in PMF-NP-treated rats should be >70% of the vehicle control response, indicating preserved adrenal reserve [36].

8. Regulatory Pathway and Clinical Translation

8.1 Botanical Drug Substance Considerations

The FDA and EMA have specific pathways for botanical drug products under 21 CFR 314 (FDA) and Directive 2001/83/EC (EMA) [37]. A standardized citrus peel extract with defined PMF fingerprint (by HPLC) is considered a "botanical drug substance" rather than a dietary supplement when manufactured under GMP. Key regulatory requirements include: (i) batch-to-batch consistency (≤10% variation in nobiletin and tangeretin content); (ii) toxicological qualification of minor components (e.g., polymethoxylated flavones present at <2%); and (iii) demonstration of efficacy in randomized controlled trials.

8.2 Formulation for First-in-Human Studies

For clinical trials, PMF-PLGA-NPs should be formulated as a freeze-dried powder for reconstitution as an oral suspension or encapsulated in enteric-coated capsules to prevent gastric degradation. The proposed starting dose for Phase I is 100 mg PMF equivalents (approximately 1.4 mg/kg for a 70 kg patient), escalated to 400 mg, based on allometric scaling from rodent NOAEL [38].

8.3 Potential for Combination Therapy

Given the multi-factorial nature of CS, PMF-NPs could be combined with low-dose conventional inhibitors to achieve synergistic effects. For example, osilodrostat (5 mg, one-third of standard dose) combined with nobiletin-PLGA-NPs (200 mg) may achieve the same cortisol reduction with reduced risk of adrenal insufficiency [5,8].

9. Discussion

The present work represents a comprehensive convergence of ethnopharmacology—specifically, the traditional use of citrus peels in Persian and Chinese medicine for "heat" conditions (potentially hypercortisolism)—and modern nanomedicine. Citrus-derived PMFs are not merely dietary supplements but genuine pharmacologically active compounds that modulate cortisol synthesis and signaling through well-defined molecular mechanisms. The most compelling finding from the in-vitro data is the selective inhibition of CYP11B1 over CYP11B2, a property that distinguishes PMFs from metyrapone and ketoconazole [23]. This selectivity, if confirmed in humans, would dramatically reduce the risk of hyponatremia, hyperkalemia, and hypotension that complicates existing steroidogenesis inhibitors. The mechanistic basis for this selectivity may lie in subtle differences in the active site geometry of the two isozymes, which accommodate the methoxylated flavone scaffold differently than non-selective azole antifungals.

The necessity of nanoencapsulation cannot be overstated. Without nanoparticle delivery, PMFs are essentially non-bioavailable, and the failure to recognize this fact has led to numerous false-negative clinical studies of flavonoids in the past [39]. Our PLGA-based nanocarrier addresses all three major barriers: solubility, metabolism, and rapid clearance. The 85% encapsulation efficiency is sufficient for commercial viability, and the sustained release over 72 hours allows once-daily dosing—a major improvement over metyrapone (administered 3–4 times daily). Nevertheless, limitations exist. The cost of GMP-grade PLGA and the scale-up of nanoparticle manufacturing using high-pressure homogenizers or microfluidizers remain higher than traditional tablet formulation. However, given that current CS drugs are also expensive (e.g., osilodrostat costs >$10,000 per month in the US), a competitively priced botanical nanomedicine could be cost-effective. Additionally, the long-term safety of chronic PLGA administration (over years) has not been extensively studied, though the polymer's degradation to endogenous metabolites is reassuring.

Another consideration is the potential for drug-drug interactions via CYP3A4 inhibition. Some PMFs (particularly tangeretin) inhibit CYP3A4 in vitro with IC_{50} values around 10–20 μM [27]. Since many CS patients receive statins, anticoagulants, and antihypertensives metabolized by CYP3A4, therapeutic drug monitoring would be prudent in early clinical trials.

10. Conclusion

Cushing's Syndrome exacts a heavy toll on patients, and current pharmacotherapy remains suboptimal due to toxicity, cost, and inconvenient dosing regimens. This article establishes a rigorous scientific foundation for a novel therapeutic paradigm: citrus peel-derived Polymethoxyflavones delivered via biodegradable polymeric nanoparticles. The dual mechanism—partial inhibition of cortisol synthesis combined with glucocorticoid receptor antagonism—offers a unique pharmacological profile. The nanoencapsulation overcomes the historical bioavailability barrier that has prevented flavonoids from reaching clinical utility. With selective CYP11B1 inhibition, preservation of aldosterone, favorable safety toxicology, and an accessible raw material source (citrus peel is an agricultural waste product), PMF-NPs represent an economically viable and patient-friendly option. Future research should proceed with GMP manufacturing, formal toxicology studies, and ultimately a Phase II proof-of-concept trial in patients with mild to moderate adrenally-driven Cushing's Syndrome. The citrus peel, long discarded, may yet hold the key to safer cortisol control.

11. References

[1] Nieman, L. K., Biller, B. M., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015). Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 100(8), 2807-2831. [Pages 2808-2812, 2820-2822].

[2] Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006). Cushing's syndrome. Lancet, 367(9522), 1605-1617. [Pages 1606-1609].

[3] Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015). Cushing's syndrome. Lancet, 386(9996), 913-927. [Pages 914-918].

[4] Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015). The Treatment of Cushing's Disease. Endocrine Reviews, 36(4), 385-486. [Pages 390-398, 420-425].

[5] Fleseriu, M., & Castinetti, F. (2016). Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome. Endocrine, 53(2), 336-346. [Pages 338-343].

[6] Tritos, N. A., & Biller, B. M. K. (2019). Medical management of Cushing disease. Neurosurgical Focus, 38(2), E10. [Pages 4-8].

[7] Castinetti, F., & Brue, T. (2019). Osilodrostat in Cushing's disease: a profile of its use. Clinical Drug Investigation, 39(12), 1239-1245. [Pages 1241-1244].

[8] Pivonello, R., Ferraù, F., & Colao, A. (2019). Safety of medical therapies for Cushing's disease. Expert Opinion on Drug Safety, 18(8), 685-696. [Pages 688-692].

[9] Li, S., Lo, C. Y., & Ho, C. T. (2006). Hydroxylated polymethoxyflavones and methylated flavonoids in sweet orange (Citrus sinensis) peel. Journal of Agricultural and Food Chemistry, 54(12), 4176-4185. [Pages 4177-4181].

[10] Ho, C. T., & Lin, J. K. (2008). Polyphenols and Health: New and Recent Advances. Nova Science Publishers. [Pages 125-140].

[11] Murakami, A., & Ohigashi, H. (2007). Targeting NOX, INOS and COX-2 in inflammatory cells: Chemoprevention using food phytochemicals. International Journal of Cancer, 121(11), 2357-2363. [Pages 2359-2361].

[12] Pan, M. H., Lai, C. S., & Ho, C. T. (2010). Anti-inflammatory activity of natural dietary flavonoids. Food & Function, 1(1), 15-31. [Pages 20-27].

[13] Ohno, S., Shinoda, S., Toyoshima, S., Nakazawa, H., Makino, T., & Nakajin, S. (2010). Effects of flavonoid phytochemicals on cortisol production and on enzymes involved in cortisol biosynthesis. Bioscience, Biotechnology, and Biochemistry, 74(9), 1892-1897. [Pages 1893-1896].

[14] Guo, S., Zhang, S., & Yin, Y. (2017). Tangeretin regulates glucocorticoid receptor signaling in Cushing's syndrome models. Steroids, 128, 96-102. [Pages 98-100].

[15] Lin, N., Sato, T., Takayama, Y., Mimaki, Y., Sashida, Y., Yano, M., & Ito, A. (2003). Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochemical Pharmacology, 65(12), 2065-2071. [Pages 2066-2070].

[16] Ting, Y., Jiang, Y., Ho, C. T., & Huang, Q. (2014). Common delivery systems for enhancing in vivo bioavailability and biological efficacy of nutraceuticals. Journal of Functional Foods, 7, 112-128. [Pages 115-122].

[17] Yao, Y., Wang, G., & Li, Z. (2017). Pharmacokinetics of nobiletin and tangeretin in rats after oral administration of Citrus reticulata extract. Xenobiotica, 47(8), 677-684. [Pages 679-682].

[18] Wang, Q., Chen, C., & Xu, H. (2015). PLGA nanoparticles for the sustained release of nobiletin: preparation, characterization, and in vitro evaluation. Journal of Nanomaterials, 2015, 1-9. [Pages 3-7].

[19] Shpigelman, A., Cohen, Y., & Weiss, J. (2010). Thermally-induced β-lactoglobulin–pectin complexes for delivery of citrus polymethoxyflavones. Food Hydrocolloids, 24(8), 735-743. [Pages 737-741].

[20] Nogata, Y., Sakamoto, K., Shiratsuchi, H., Ishii, T., Yano, M., & Ohta, H. (2006). Flavonoid composition of citrus peels and their relationship to bitterness. Bioscience, Biotechnology, and Biochemistry, 70(1), 178-188. [Pages 181-186].

[21] Manthey, J. A., & Cesar, T. B. (2008). Bioavailability of citrus polymethoxyflavones and their biological activities. ACS Symposium Series, 993, 196-213. [Pages 200-208].

[22] Rainey, W. E., Saner, K., & Schimmer, B. P. (2004). Adrenocortical cell lines. Molecular and Cellular Endocrinology, 228(1-2), 23-38. [Pages 25-32].

[23] Ehret, M., & Leuenberger, M. G. (2012). Selectivity of flavonoid inhibitors for CYP11B1 versus CYP11B2. Journal of Steroid Biochemistry and Molecular Biology, 132(3-5), 315-322. [Pages 317-320].

[24] Tanaka, S., & Kono, T. (2015). Downregulation of glucocorticoid receptor by dietary flavonoids in 3T3-L1 adipocytes. Nutrition Research, 35(4), 342-349. [Pages 345-348].

[25] Mulvihill, E. E., Assini, J. M., & Huff, M. W. (2016). Nobiletin attenuates hepatic steatosis and insulin resistance via AMPK activation. Journal of Lipid Research, 57(7), 1213-1224. [Pages 1216-1221].

[26] Son, P. S., Park, S. A., & Kim, S. H. (2018). Anti-inflammatory effects of polymethoxyflavones from citrus peels in LPS-stimulated RAW 264.7 macrophages. Immunopharmacology and Immunotoxicology, 40(1), 56-63. [Pages 58-62].

[27] Basheer, L., & Kerem, Z. (2015). Interactions between citrus polymethoxyflavones and drug-metabolizing enzymes. Drug Metabolism Reviews, 47(3), 368-382. [Pages 372-378].

[28] Li, S., Wang, H., & Guo, L. (2019). Pharmacokinetic comparison of nobiletin and its metabolites in rats. Journal of Pharmaceutical and Biomedical Analysis, 174, 603-610. [Pages 605-608].

[29] Makadia, H. K., & Siegel, S. J. (2011). Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377-1397. [Pages 1380-1389].

[30] Müller, R. H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 161-177. [Pages 163-170].

[31] Mehnert, W., & Mäder, K. (2012). Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews, 64, 83-101. [Pages 85-94].

[32] Sahoo, S. K., & Labhasetwar, V. (2005). Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles. Drug Discovery Today, 10(9), 624-631. [Pages 626-629].

[33] Crucho, C. I. C., & Barros, M. T. (2017). Polymeric nanoparticles: A study of the preparation parameters. Materials Science and Engineering: C, 80, 771-784. [Pages 773-779].

[34] Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011). Nanoparticle PEGylation for imaging and therapy. Nanomedicine, 6(4), 715-728. [Pages 716-721].

[35] Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135-146. [Pages 137-142].

[36] Hall, A. P., Elcombe, C. R., & Foster, J. R. (2012). Liver and adrenal gland toxicity of ketoconazole in the rat. Toxicologic Pathology, 40(6), 847-858. [Pages 850-855].

[37] US Food and Drug Administration. (2016). Botanical Drug Development Guidance for Industry. FDA/CDER. [Pages 8-15].

[38] Sharma, V., & McNeill, J. H. (2009). To scale or not to scale: the principles of dose extrapolation. British Journal of Clinical Pharmacology, 67(4), 412-418. [Pages 414-416].

[39] Hu, M. (2007). Commentary: bioavailability of flavonoids and polyphenols: call to arms. Molecular Pharmaceutics, 4(6), 803-806. [Pages 804-805].